Celyad Oncology (LTS:0QFK) FFO


LTS:0QFK Celyad Oncology SA LTS:0QFK
13 GF Score
Price €0.23
GF Value €0.67
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Celyad Oncology FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0QFK
13GF Score
Celyad Oncology SA LTS:0QFK
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Celyad Oncology (LTS:0QFK) Overvalued in 2026?

Based on GuruFocus' analysis, Celyad Oncology stock appears to be undervalued. The current stock price of €0.23 is trading 65% below its estimated GF Value™ of €0.67. GuruFocus considers Celyad Oncology to be Possible Value Trap.

Key valuation signals for LTS:0QFK:

  • FFO:
  • GF Value™: €0.67 vs. price of €0.23 (65% below fair value)
  • GF Score™: 13/100 with 6 warning signs

No single metric tells the full story. See the LTS:0QFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celyad Oncology Business Description

Address Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
13GF Score

Get the complete analysis for LTS:0QFK

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.23
Price
€0.67
GF Value